Sex Chromosomes and Activin-A Influence TNFR2-Based Therapy in MS and CNP Models

Rapid Summary

• A study published in the Proceedings of the National Academy of Sciences (Volume 122, Issue 20, May 2025) examines how sex-chromosome complement and gonadal Activin-A influence therapeutic outcomes in treating motor deficits and chronic neuropathic pain (CNP) associated with multiple sclerosis (MS).
• The research focuses on utilizing TNFR2 activation as a therapy to mitigate these symptoms in a MS model.

Indian Opinion Analysis
This research holds potential significance for India, where neurological disorders like MS are growing concerns amidst limited access to advanced therapies. Findings on sex-chromosomal influences and specific biological markers such as Activin-A could pave the way for targeted treatments tailored to diverse patient populations. For India’s medical community, this study underlines the importance of investing further in biotechnological research that aligns with global advancements while considering regional health challenges. Accessibility and affordability remain critical factors moving forward.

Read More